Avastin is dosed at four to six-week intervals for AMD, while Eylea is given every four to eight weeks and Lucentis once a month. Novartis is developing a follow-on drug – brolucizumab – that ...

Novartis ups the ante in the wet AMD market battle with Bayer/Regeneron’s Eylea, launching a trial that will test 16-week dosing for its new antibody brolucizumab.

We are initiating coverage of biosimilar manufacturer Celltrion. Its current flagship drugs include biosimilars to Remicade, Rituxan, Herceptin, and Avastin. The bottom line: We initiate with a ...

As we understand it, this is a much higher dosage, which is able to extend for almost up to 16 weeks, but my preference for Eylea HD is very much to the patient, where, you know, we know that they ...

The introduction of the first-generation anti-VEGF drugs—Macugen (pegaptanib), Eylea (aflibercept), Lucentis (ranibizumab), and Avastin (bevacizumab)—has since been followed by longer-lasting agents ...

Regeneron is facing biosimilar competition for Eylea, one of its biggest growth drivers. In the first quarter, the company's revenue decreased by 4% year over year to $3 billion.

This recent occurrence has intensified the existing pressures on REGN stock. At present, trading at $490, the stock has decreased 60% from its 52-week peak of about $1,200.

Unlike the original shot, Eylea HD won't be susceptible to less-expensive biosimilars for some time. It's given every four weeks for the first three doses, followed by a dose every eight to 16 weeks.

Bristol Myers Squibb said Monday it will pay the German firm BioNTech billions of dollars to split rights for an experimental cancer drug called BNT327, which works on both PD-L1, the target of ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...